Standard BioTools
LAB
104 hedge funds and large institutions have $1.29B invested in Standard BioTools in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 36 reducing their positions, and 11 closing their positions.
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
26% more capital invested
Capital invested by funds: $1.02B → $1.29B (+$264M)
11% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 36
4% more funds holding
Funds holding: 100 → 104 (+4)
32% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.6M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$9.96M |
| 2 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$6.73M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$6.71M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.39M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.08M |
LAB Hedge Fund Activity: Q1 2015 in Review
104 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2015, worth a combined $1.29B — up 26% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LAB positions and 11 closed out — a net gain of 5 holders — while 40 added to existing stakes and 36 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $15.6M. The largest seller was JP Morgan Chase, cutting an estimated $9.96M.
- 104 institutional investors held Standard BioTools (LAB) as of Q1 2015, up from 100 in Q4 2014.
- Funds reported $1.29B of Standard BioTools stock for Q1 2015, up 26% quarter-over-quarter.
- 16 funds opened new Standard BioTools positions in Q1 2015 and 11 closed out, a net change of +5 holders.
- The largest Standard BioTools buyer in Q1 2015 was Lord, Abbett & Co, an estimated $15.6M added.
- The largest Standard BioTools seller in Q1 2015 was JP Morgan Chase, an estimated $9.96M sold.
Based on aggregated 13F filings for Q1 2015.